Home
HelpTest Code ATPCO Anal ThinPrep Cytology with Human Papillomavirus (HPV) Co-Test, Varies
Necessary Information
1. The following information must accompany the specimen: Patient's name, medical record number, date of birth, sex, source (exact location and procedure used), date specimen was taken, name of ordering physician and pager number.
2. Submit any pertinent history or clinical information.
Specimen Required
Supplies: PreservCyt Vial (T536)
Specimen Type: Anus or rectum
Container/Tube: ThinPrep/PreservCyt solution vial
Specimen Volume: A minimum of 20 mL or entire collection
Collection Instructions:
1. Visualize the anal opening by retracting the buttocks.
2. Moisten Dacron or polyester swab past internal anal sphincter until it abuts the distal rectal wall (4-5cm).
3. Rotate the swab 360 degrees and maintain lateral pressure on swab against the walls of the anus. The swab should bow slightly due to the pressure.
4. While rotating, slowly withdraw the swab.
5. Rotate at least 10 times while withdrawing the swab. This should take 20 to 30 seconds.
6. Immediately place swab in the ThinPrep solution. Swish at least 20 to 30 seconds in the ThinPrep solution.
7. Dispose of the swab.
8. Tighten the cap so that the torque line on the cap passes the torque line on the vial.
9. Place labels on the vial and on the bag.
10. Bag ThinPrep specimens individually as they tend to leak during transport.
Useful For
Detection of malignant and premalignant changes
Detection of high-risk (HR) genotypes associated with the development of anal cancer
Individual genotyping of human papillomavirus (HPV)-16 and HPV-18, if present
May aid in triaging men and women with positive HR-HPV but negative anal Pap smear results
The cobas HPV test is not recommended for evaluation of suspected sexual abuse.
Additional Tests
| Test ID | Reporting Name | Available Separately | Always Performed |
|---|---|---|---|
| AHPV | HPV Anal Detect / Genotyping PCR | No | Yes |
Testing Algorithm
When this test is ordered, a cytology screen and genotyping for high-risk human papillomavirus types will be performed.
Method Name
ATPCO: Light Microscopy
AHPV: Real-Time Polymerase Chain Reaction (PCR)
Reporting Name
Anal ThinPrep Cytology w/HPV CoTestSpecimen Type
VariesSpecimen Minimum Volume
See Specimen Required
Specimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Varies | Ambient | 21 days | THIN PREP |
Reject Due To
| SurePath vial Specimen containing CytoRich Red preservative fluid |
Reject |
Clinical Information
Persistent infection with human papillomavirus (HPV) can cause anal cancer, with approximately 90% of all anal cancers being associated with HPV infection. HPV is a small, nonenveloped, double-stranded DNA virus, with a genome of approximately 8000 nucleotides. There are more than 118 different types of HPV and approximately 40 different HPVs that can infect the human anogenital mucosa. However, data suggest that 14 of these types (HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68) are considered high-risk (HR) for the development of cervical and anal cancer and precursor lesions. Furthermore, HPV types 16 and 18 have been regarded as the genotypes most closely associated with progression to cancer. HPV-16 is the most carcinogenic and is associated with approximately 60% of all HPV-related cancers, while HPV-18 accounts for approximately 10% to 15% of HPV-related cancers.(1-3)
Sexually transmitted infection with HPV is extremely common, with estimates of up to 75% of all women being exposed to HPV at some point. However, almost all infected patients will mount an effective immune response and clear the infection within 2 years without any long-term health consequences.
DNA testing by real-time polymerase chain reaction (PCR) is a noninvasive method for determining the presence of anal HPV infection. Proper implementation of DNA testing for HPV may:
1. Increase the sensitivity of anal cancer detection
2. Reduce the need for unnecessary biopsy and treatment
Recently, data suggest that individual genotyping for HPV types 16 and 18 can assist in determining appropriate follow-up testing and triaging of patients who are at risk for cervical cancer and may be useful in cases of possible anal cancer. Detection of HRHPV DNA, especially genotypes 16 and 18, may assist in triaging patients and determining appropriate management strategies.
Reference Values
ThinPrep ANAL SWAB
Satisfactory for evaluation. Negative for intraepithelial lesion or malignancy.
HUMAN PAPILLOMAVIRUS (HPV)
Negative for HPV genotypes 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68
Interpretation
Cytology:
Suspicious or atypical results need further confirmation: clinical observation, repeat cytology, or perhaps appropriate biopsy.
Positive results should be confirmed by histologic examination of tissue before definitive therapy is instituted.
Human papillomavirus:
A positive result indicates the presence of human papillomavirus (HPV) DNA due to 1 or more of the following genotypes: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68.
A negative result indicates the absence of HPV DNA of the targeted genotypes. Management of abnormal results requires consideration of baseline risk of anal cancer and prior anal cytology and HPV results.
For patients with an anal Pap test result showing atypical squamous cells of undetermined significance (ASC-US) and who are positive for high-risk (HR) HPV, consider referral for anoscopy, if clinically indicated.
For men and women with a negative anal Pap test result but who are positive for HPV-16 or HPV-18, consider referral for anoscopy, if clinically indicated.
For men and women with a negative anal Pap smear, positive-HR-HPV test result, but who are negative for HPV-16 and HPV-18, consider repeat testing by both cytology and HR-HPV in 12 months.
Cautions
Cytology: No significant cautionary statements
Human papillomavirus:
The cobas human papillomavirus (HPV) test is US Food and Drug Administration (FDA) approved for cervical and endocervical samples collected in PreservCyt (ThinPrep) media. Other specimen types (eg, anal) are not considered FDA-approved sources; however, verification studies have been completed by Mayo Clinic Laboratories and Mayo Clinic in compliance with CLIA regulations.
The cobas HPV test detects DNA of the high-risk types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68. This test does not detect DNA of HPV low-risk types (eg, 6, 11, 42, 43, 44) since these are not associated with cervical cancer and its precursor lesions.
Prevalence of HPV infection in a population may affect performance. Positive-predictive values decrease when testing populations with low prevalence or individuals with no risk of infection.
Infection with HPV is not an indicator of cytologic high-grade squamous intraepithelial lesion (HSIL) or underlying high-grade cervical intraepithelial neoplasia (CIN), nor does it imply that CIN2-3 or cancer will develop. Most patients infected with 1 or more high-risk (HR) HPV types do not develop CIN2-3 or cancer.
A negative HR-HPV result does not exclude the possibility of future cytologic HSIL or underlying CIN2-3 or cancer.
Anal specimens may show visibly detectable levels of whole blood or stool as a pink or light brown coloration. These specimens are processed normally on the cobas 4800 System. If concentrations of whole blood or stool are high, results may be impacted.
The cobas HPV test performance has not been validated with PreservCyt specimens that have been treated with glacial acetic acid for removal of red blood cells. Any such processing of PreservCyt specimens prior to HPV testing would invalidate the cobas HPV test results.
The cobas HPV test performance has not been validated with PreservCyt specimens that have been filled past the maximum fill line of the primary vial. ThinPrep vials that have had any additional PreservCyt fluid volume added or any dissimilar fluid volume added to the initial specimen should not be submitted for testing.
HPV-negative cancers of the cervix or anus do occur in rare circumstances. Also, no cancer screening test is 100% sensitive. Use of this device for primary anal cancer screening should be undertaken after carefully considering the performance characteristics put forth in the cobas HPV test label, as well as recommendations of professional guidelines.
The presence of real-time polymerase chain reaction inhibitors may cause false negative or invalid results.
Anal specimens that are grossly contaminated with stool may yield invalid or false negative results.
Day(s) Performed
Monday through Friday
Report Available
3 to 6 daysPerforming Laboratory
Mayo Clinic Laboratories in Rochester
Test Classification
This test has been modified from the manufacturer's instructions. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
ATPCO – 88112
AHPV - 87624
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| ATPCO | Anal ThinPrep Cytology w/HPV CoTest | In Process |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| 614403 | Interpretation | 69965-2 |
| 614404 | Participated in the Interpretation | No LOINC Needed |
| 614405 | Report electronically signed by | 19139-5 |
| 614406 | Addendum | 35265-8 |
| 614407 | Gross Description | 22634-0 |
| CY088 | Source | 22633-2 |
| CY089 | Clinical History | 22636-5 |
| 614408 | Disclaimer | 62364-5 |
| 614409 | Case Number | 80398-1 |